SCHEMBL1015370

SCHEMBL1015370

COC(=O)c1cc(Cl)ccc1NC(=O)COCC(=O)O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.60
TSHR P16473 2/20 0.51
ALDH1A1 P00352 5/20 0.51
GAA P10253 2/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
RXFP1 Q9HBX9 1/20 0.49
MAPT P10636 5/20 0.49
MEN1 O00255 1/20 0.49
POLB P06746 1/20 0.49
MAPK1 P28482 1/20 0.49
KMT2A Q03164 1/20 0.49
LMNA P02545 2/20 0.49
TP53 P04637 2/20 0.48
THRB P10828 1/20 0.48
HSD17B10 Q99714 3/20 0.48
USP2 O75604 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1801205 0.90 KDM4E (0.60) KDM4ETSHRALDH1A1SMN1; SMN2MAPT
SCHEMBL1797516 0.88 ALDH1A1 (0.50) KDM4EALDH1A1GAASMN1; SMN2CYP1A2
SCHEMBL7125633 0.88 ALDH1A1 (0.62) KDM4EALDH1A1GAASMN1; SMN2CYP1A2
SCHEMBL1794335 0.87 SMN1; SMN2 (0.69) KDM4EALDH1A1GAASMN1; SMN2CYP1A2
SCHEMBL9674267 0.86 ALDH1A1 (0.65) KDM4EALDH1A1GAASMN1; SMN2CYP1A2
SCHEMBL1800306 0.84 TSHR (0.51) KDM4ETSHRALDH1A1CYP1A2CYP2C19
SCHEMBL1796641 0.84 ALDH1A1 (0.57) KDM4ETSHRALDH1A1GAAMAPT
SCHEMBL1798978 0.84 SERPINE1 (0.53) KDM4ETSHRALDH1A1GAASMN1; SMN2
SCHEMBL1799240 0.84 MAPT (0.49) KDM4ETSHRALDH1A1GAASMN1; SMN2
SCHEMBL1794963 0.83 SERPINE1 (0.52) KDM4ETSHRALDH1A1GAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8415479-B2 Inhibitor of plasminogen activator inhibitor-1 RENASCIENCE CO., LTD. (JP) 2013-04-09 US disclosed
US-7951806-B2 Plasminogen activator inhibitor-1 inhibitor RENASCIENCE CO., LTD. (JP) 2011-05-31 US disclosed
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 RENASCIENCE CO., LTD. (JP) 2011-05-12 US disclosed
EP-2272822-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 Renascience CO., LTD. (JP) 2011-01-12 EP disclosed
US-20090124620-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR RENASCIENCE CO., LTD. (JP) 2009-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 SERPINE1, SERPINB1, SERPINC1 KDM4E 4108/4885TSHR 2763/4885ALDH1A1 888/4885
US-20090124620-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 KDM4E 4309/4885TSHR 2186/4885ALDH1A1 800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.